Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next?Defense World · 4 days ago
Immutep Receives ~A$0.86 Million R&D Tax IncentiveGlobeNewsWire · Sep 30, 2026
Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4%Defense World · Aug 31, 2026
Prima BioMed (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average – Should You Sell?Defense World · Aug 14, 2026Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 30, 2026 | -$0.52 | -$3.11 | Miss |
| Feb 24, 2026 | -$0.20 | -$0.22 | Miss |
| Aug 29, 2025 | -$3.72 | -$3.72 | Beat |
| Feb 26, 2025 | -$0.14 | -$0.10 | Beat |
| Aug 29, 2024 | -$0.13 | -$0.12 | Beat |
| Apr 29, 2024 | -$2.50 | -$2.41 | Beat |